The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
Stock Performance Overview: The Zacks Equity Research highlights recent stock performances, noting AbbVie Inc. and TJX Companies have outperformed their respective industries, while Charles Schwab and Enzo Biochem face challenges affecting their growth prospects.
Market Insights and Reports: Daily research reports from Zacks provide insights into market trends and economic releases, with a focus on how these factors influence trading actions, alongside recommendations for investors to stay informed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 232.080
Low
223.00
Averages
252.00
High
289.00
Current: 232.080
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ABBVIE: RISANKIZUMAB SC INDUCTION DEMONSTRATES A SAFETY PROFILE CONSISTENT WITH PREVIOUS FINDINGS IN CROHN'S DISEASE
- Safety Profile: The safety profile of Risankizumab is consistent with its known profile in Crohn's disease.
- Clinical Relevance: The findings reinforce the drug's established safety and efficacy in treating the condition.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
AbbVie: A Strong Dividend Investment Choice
- Dividend Yield Advantage: AbbVie offers a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1%, making it an attractive choice for long-term investors seeking steady cash flow for their portfolios.
- Consistent Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, which not only boosts investor confidence but also indicates the company's capability to combat inflation effectively.
- Strong Cash Flow: Despite a payout ratio exceeding 100%, AbbVie reported a free cash flow of $17.8 billion last year, far surpassing the $11.7 billion paid in dividends, demonstrating its robust financial health.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion by 2025, showcasing its strong growth potential.
See More
AbbVie Increases Dividend by Over 330% Since IPO
- Significant Dividend Growth: AbbVie has increased its dividend by over 330% since its IPO in 2013, currently offering a yield of 2.9%, which is substantially higher than the S&P 500 average of 1.1%, indicating the company's stability and growth potential in dividend payments.
- Strong Cash Flow Support: Last year, AbbVie generated $17.8 billion in free cash flow, significantly exceeding its $11.7 billion in dividend payments, which, despite a payout ratio over 100%, demonstrates robust cash flow capabilities for sustaining dividends.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion and a growth rate of 9% by 2025, showcasing its ability to continuously develop new drugs and acquire companies.
- Enhanced Investor Confidence: Although AbbVie was not included in the current top investment stocks identified by analysts, its stable dividend and strong growth prospects make it an ideal choice for long-term investors, providing a reliable cash flow for their portfolios.
See More
AbbVie Reports Promising Phase 3 Results for Crohn's Disease Treatment
- Clinical Trial Results: AbbVie's AFFIRM study revealed that 55% of Crohn's disease patients treated with risankizumab achieved clinical remission at week 12, compared to only 30% in the placebo group, indicating the drug's potential in treating refractory patients.
- Significant Endoscopic Response: The study found that 44% of patients experienced an endoscopic response, significantly higher than the 14% in the placebo group, reinforcing risankizumab's position as a leading treatment option for Crohn's disease.
- Market Competition Analysis: William Blair noted that the positive results are strategically important for Skyrizi's competitive positioning against Johnson & Johnson's Tremfya, as AbbVie now has the opportunity to pursue a fully subcutaneous Skyrizi induction regimen, narrowing the convenience gap with Tremfya.
- Stock Performance Analysis: AbbVie shares were trading at $232.82, 4.5% above its 20-day simple moving average, indicating a strong upward trend, although the RSI and MACD suggest potential short-term headwinds.
See More
AbbVie's Skyrizi Subcutaneous Trial Achieves Key Milestones
- Clinical Trial Success: AbbVie's Skyrizi (risankizumab) achieved significant results in a phase 3 trial for Crohn's disease, with a clinical remission rate of 55% at week 12 for patients receiving Skyrizi SC compared to 30% for placebo, demonstrating the drug's efficacy.
- Enhanced Endoscopic Response: The same trial showed an endoscopic response rate of 44% for the Skyrizi SC group, significantly higher than the 14% for the placebo group, indicating the drug's potential in improving patients' intestinal health.
- Long-term Efficacy Observed: After 12 weeks of Skyrizi SC treatment, 67% of patients achieved CDAI clinical remission at week 24, and 57% achieved endoscopic response, showcasing the drug's durable efficacy and promising therapeutic outlook.
- Positive Market Outlook: With Skyrizi's success in immunology, AbbVie further solidifies its leadership in the biopharmaceutical market and lays the groundwork for future oncology developments, attracting positive attention from analysts.
See More
ABBVIE: RISANKIZUMAB SC INDUCTION DEMONSTRATES A SAFETY PROFILE CONSISTENT WITH PREVIOUS FINDINGS IN CROHN'S DISEASE
- Safety Profile: The safety profile of Risankizumab is consistent with its known profile in Crohn's disease.
- Clinical Relevance: The findings reinforce the drug's established safety and efficacy in treating the condition.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
AbbVie: A Strong Dividend Investment Choice
- Dividend Yield Advantage: AbbVie offers a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1%, making it an attractive choice for long-term investors seeking steady cash flow for their portfolios.
- Consistent Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, which not only boosts investor confidence but also indicates the company's capability to combat inflation effectively.
- Strong Cash Flow: Despite a payout ratio exceeding 100%, AbbVie reported a free cash flow of $17.8 billion last year, far surpassing the $11.7 billion paid in dividends, demonstrating its robust financial health.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion by 2025, showcasing its strong growth potential.
See More
AbbVie Increases Dividend by Over 330% Since IPO
- Significant Dividend Growth: AbbVie has increased its dividend by over 330% since its IPO in 2013, currently offering a yield of 2.9%, which is substantially higher than the S&P 500 average of 1.1%, indicating the company's stability and growth potential in dividend payments.
- Strong Cash Flow Support: Last year, AbbVie generated $17.8 billion in free cash flow, significantly exceeding its $11.7 billion in dividend payments, which, despite a payout ratio over 100%, demonstrates robust cash flow capabilities for sustaining dividends.
- Diverse Growth Opportunities: AbbVie has a rich product portfolio across oncology, neuroscience, aesthetics, eye care, and immunology, with projected net revenue of $61.2 billion and a growth rate of 9% by 2025, showcasing its ability to continuously develop new drugs and acquire companies.
- Enhanced Investor Confidence: Although AbbVie was not included in the current top investment stocks identified by analysts, its stable dividend and strong growth prospects make it an ideal choice for long-term investors, providing a reliable cash flow for their portfolios.
See More
AbbVie Reports Promising Phase 3 Results for Crohn's Disease Treatment
- Clinical Trial Results: AbbVie's AFFIRM study revealed that 55% of Crohn's disease patients treated with risankizumab achieved clinical remission at week 12, compared to only 30% in the placebo group, indicating the drug's potential in treating refractory patients.
- Significant Endoscopic Response: The study found that 44% of patients experienced an endoscopic response, significantly higher than the 14% in the placebo group, reinforcing risankizumab's position as a leading treatment option for Crohn's disease.
- Market Competition Analysis: William Blair noted that the positive results are strategically important for Skyrizi's competitive positioning against Johnson & Johnson's Tremfya, as AbbVie now has the opportunity to pursue a fully subcutaneous Skyrizi induction regimen, narrowing the convenience gap with Tremfya.
- Stock Performance Analysis: AbbVie shares were trading at $232.82, 4.5% above its 20-day simple moving average, indicating a strong upward trend, although the RSI and MACD suggest potential short-term headwinds.
See More
AbbVie's Skyrizi Subcutaneous Trial Achieves Key Milestones
- Clinical Trial Success: AbbVie's Skyrizi (risankizumab) achieved significant results in a phase 3 trial for Crohn's disease, with a clinical remission rate of 55% at week 12 for patients receiving Skyrizi SC compared to 30% for placebo, demonstrating the drug's efficacy.
- Enhanced Endoscopic Response: The same trial showed an endoscopic response rate of 44% for the Skyrizi SC group, significantly higher than the 14% for the placebo group, indicating the drug's potential in improving patients' intestinal health.
- Long-term Efficacy Observed: After 12 weeks of Skyrizi SC treatment, 67% of patients achieved CDAI clinical remission at week 24, and 57% achieved endoscopic response, showcasing the drug's durable efficacy and promising therapeutic outlook.
- Positive Market Outlook: With Skyrizi's success in immunology, AbbVie further solidifies its leadership in the biopharmaceutical market and lays the groundwork for future oncology developments, attracting positive attention from analysts.
See More
